Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
RegulatoryapprovedREVTORPYKPositive
AI Analysis
Summary
Celcuity announced FDA approval of REVTORPYK (gedatolisib) for treating HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer, representing a significant regulatory milestone for the company.
Outcome Details
FDA approval of REVTORPYK (gedatolisib) for HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
Importance:9/10
Sentiment:
0.95
FDA ApprovalOncologyBreast CancerCommercial Launch
Related Companies
Read the original article
Published by yahoo_finance on July 14, 2026 8:53 PM